NCT04393454: Study to Evaluate the Efficacy and Safety of Sirolimus in Subjects With Metastatic, Mismatch Repair Deficient Solid Tumors After Immunotherapy

NCT04393454: Study to Evaluate the Efficacy and Safety of Sirolimus in Subjects With Metastatic, Mismatch Repair Deficient Solid Tumors After Immunotherapy

NCT04393454
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: MMR
Breast Cancer Tissue:
Recruitment Status: Recruiting
Phase 2
Drug Category: Other, Serine-Threonine Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years to 65 Years (Adult, Older Adult)
Location of Metastases:
Additional Notes:
Exclusions: Patients with symptomatic central nervous system (CNS) metastases
https://ClinicalTrials.gov/show/NCT04393454